| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JCHF.2012.12.004 |
| P698 | PubMed publication ID | 24621834 |
| P50 | author | Chris Garratt | Q83714776 |
| John R Teerlink | Q90422543 | ||
| P2093 | author name string | James Young | |
| Milton Packer | |||
| Robert J Padley | |||
| Barry M Massie | |||
| Bidan Huang | |||
| Lloyd Fisher | |||
| Leticia Delgado-Herrera | |||
| Toni Sarapohja | |||
| Roopal Thakkar | |||
| Wilson Colucci | |||
| Jeffrey Salon | |||
| REVIVE Heart Failure Study Group | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| heart failure | Q181754 | ||
| P304 | page(s) | 103-111 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | JACC: Heart Failure | Q26841917 |
| P1476 | title | Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure | |
| P478 | volume | 1 |
| Q34995668 | 2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure |
| Q57396164 | Acute heart failure: have we got it all wrong? |
| Q57911301 | Acute heart failure: lessons learned, roads ahead |
| Q56381075 | Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology |
| Q30394479 | Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations |
| Q38959942 | Agents with vasodilator properties in acute heart failure |
| Q28084239 | Agents with vasodilator properties in acute heart failure: how to design successful trials |
| Q44143731 | Almanac 2013: heart failure |
| Q90211680 | Ambulatory Inotrope Infusions in Advanced Heart Failure: A Systematic Review and Meta-Analysis |
| Q26800965 | Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review |
| Q90057040 | Atrial Cardiomyopathy: An Unexplored Limb of Virchow's Triad for AF Stroke Prophylaxis |
| Q38573100 | Autonomic Dysregulation as a Therapeutic Target for Acute HF. |
| Q37019674 | Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. |
| Q42653967 | Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials |
| Q57665132 | CSI position statement on management of heart failure in India |
| Q47156125 | CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat. |
| Q38939243 | Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe? |
| Q28085736 | Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs |
| Q64088256 | Clinical profiles in acute heart failure: an urgent need for a new approach |
| Q51655639 | Comparison of the Effects of Levosimendan Dobutamine and Vasodilator Therapy on Ongoing Myocardial Injury in Acute Decompensated Heart Failure. |
| Q26801166 | Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies |
| Q38588160 | Critical care for paediatric patients with heart failure |
| Q35675983 | De novo acute heart failure and acutely decompensated chronic heart failure |
| Q26750884 | Decongestion: Diuretics and other therapies for hospitalized heart failure |
| Q48283568 | Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials? |
| Q36385581 | Differences in health care use and outcomes by the timing of in-hospital worsening heart failure |
| Q35789263 | Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort |
| Q46143451 | Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction |
| Q39154039 | Diuretic Strategies in Acute Decompensated Heart Failure |
| Q38307958 | Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy |
| Q88599261 | Drugs' development in acute heart failure: what went wrong? |
| Q44129824 | Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial |
| Q38292123 | Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis |
| Q50060231 | Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. |
| Q48073496 | Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial |
| Q38694200 | Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype? |
| Q38238450 | Emerging role of serelaxin in the therapeutic armamentarium for heart failure |
| Q26796261 | European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society |
| Q38571627 | European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. |
| Q47757313 | From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research |
| Q53707293 | Haemodynamic effects of levosimendan in advanced but stable chronic heart failure. |
| Q87917890 | Heart failure management-time to change our script on prognosis? |
| Q43742216 | Heart failure. Tardy but intact--publication of REVIVE trial results welcomed. |
| Q88711553 | How to Improve Time to Diagnosis in Acute Heart Failure - Clinical Signs and Chest X-ray |
| Q38705811 | Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure |
| Q90299408 | Impact of early treatment with intravenous vasodilators and blood pressure reduction in acute heart failure |
| Q37460428 | Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery - a retrospective analysis. |
| Q38388972 | Implications of Using Different Definitions on Outcomes in Worsening Heart Failure |
| Q38559347 | In-hospital worsening heart failure |
| Q35026394 | In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization |
| Q38173317 | Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond |
| Q42198249 | Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart |
| Q41034753 | Initial Observations of the Effects of Calcium Chloride Infusions in Pediatric Patients with Low Cardiac Output |
| Q47707958 | Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome |
| Q94566824 | Istaroxime in acute heart failure: the holy grail is at HORIZON? |
| Q97884755 | Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use |
| Q92335563 | Levosimendan and systemic vascular resistance in cardiac surgery patients: a systematic review and meta-analysis |
| Q41226308 | Levosimendan improves exercise performance in patients with advanced chronic heart failure. |
| Q45742045 | Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms |
| Q58605947 | Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application |
| Q38620002 | Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications. |
| Q55057539 | Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: a meta-analysis and trial sequential analysis of randomized trials. |
| Q89443434 | Levosimendan in pulmonary hypertension and right heart failure |
| Q26765449 | Levosimendan meta-analyses: Is there a pattern in the effect on mortality? |
| Q47793271 | Levosimendan prevents bronchoconstriction and adverse respiratory tissue mechanical changes in rabbits |
| Q54257049 | Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy. |
| Q24629274 | Levosimendan: current data, clinical use and future development |
| Q38734731 | Long-term intravenous inotropes in low-output terminal heart failure? |
| Q90753855 | Mega-trials in heart failure: effects of dilution in examination of new therapies |
| Q39188101 | Modern drug therapy in cardiovascular intensive care medicine |
| Q39218629 | New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations |
| Q38248398 | New drugs and devices in the pipeline for heart failure with reduced ejection fraction versus heart failure with preserved ejection fraction |
| Q92052387 | New perspectives and future directions in the treatment of heart failure |
| Q89447793 | New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis |
| Q42696155 | Newer drugs for heart failure: hype or hope? |
| Q38639973 | Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure |
| Q38409693 | Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study |
| Q49506557 | Outpatient Worsening Heart Failure as a Target for Therapy: A Review. |
| Q39249844 | Pharmacological and Non-pharmacological Treatment for Decompensated Heart Failure: What Is New? |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q88711524 | Pulmonary Oedema-Therapeutic Targets |
| Q88841221 | RELAX-AHF, BLAST-AHF, TRUE-AHF, and other important truths in acute heart failure research |
| Q38927295 | Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure |
| Q37154191 | Rationale and design of the multicenter randomized trial investigating the effects of levosimendan pretreatment in patients with low ejection fraction (≤40 %) undergoing CABG with cardiopulmonary bypass (LICORN study). |
| Q39174741 | Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure |
| Q94585840 | Reappraisal on pharmacological and mechanical treatments of heart failure |
| Q57822514 | Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure |
| Q46072220 | Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. |
| Q37314324 | Renal effects of levosimendan: a consensus report |
| Q88554029 | Repetitive levosimendan for a LION's heart? |
| Q38215304 | Serelaxin : a potential new drug for the treatment of acute heart failure |
| Q38798476 | Serelaxin for the treatment of heart failure |
| Q33845755 | Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study |
| Q28607749 | Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs |
| Q39200790 | Systolic Blood Pressure on Admission and Mortality in Patients Hospitalized With Acute Heart Failure: Observations From the Gulf Acute Heart Failure Registry. |
| Q46833198 | Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? |
| Q28260629 | Targeting the sarcomere to correct muscle function |
| Q36168137 | The Impact of Worsening Heart Failure in the United States |
| Q58701200 | The calcium sensitizer drug MCI-154 binds the structural C-terminal domain of cardiac troponin C |
| Q51066753 | The effects of levosimendan on renal function early after heart transplantation: results from a pilot randomized trial. |
| Q47097922 | The inodilator levosimendan as a treatment for acute heart failure in various settings. |
| Q47156435 | The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure |
| Q47158526 | The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure |
| Q92158470 | Therapeutic Advances in the Management of Acute Decompensated Heart Failure |
| Q38267665 | Therapeutic adjustments in stage D heart failure: challenges and strategies |
| Q104137178 | Time-sensitive approach in the management of acute heart failure |
| Q38806549 | Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency |
| Q88160208 | Understanding worsening heart failure as a therapeutic target: another step forward? |
| Q26774435 | Use of Inotropic Agents in Treatment of Systolic Heart Failure |
| Q60950194 | Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper |
| Q92236838 | Use of levosimendan in acute and advanced heart failure: short review on available real-world data |
| Q59789293 | Use of levosimendan in acute heart failure |
| Q35767495 | Use of levosimendan in patients with heart failure in different settings: case reports and treatment guidance. |
| Q26771479 | What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? |
| Q92588956 | Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials |
| Q58371147 | Why is heart failure so important in the 21st century? |
| Q36089337 | Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) |
| Q39856310 | Worsening heart failure in 'real-world' clinical practice: predictors and prognostic impact. |
| Q57396169 | Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study |
Search more.